Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

159.37 +1.45 (+0.92%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,957,341
Open 158.43
Bid (Size) 157.41 (1)
Ask (Size) 160.00 (1)
Prev. Close 157.92
Today's Range 157.73 - 159.57
52wk Range 134.09 - 175.91
Shares Outstanding N/A
Dividend Yield 3.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Top Healthcare Stocks to Buy With $100
With the right stocks, even a small investment can yield huge returns. 
Via The Motley Fool
ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash
Key Takeaways: ImmuneOnco’s main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the... 
Via Benzinga

Performance

YTD
-1.85%
-1.85%
1 Month
+2.64%
+2.64%
3 Month
-1.39%
-1.39%
6 Month
+18.75%
+18.75%
1 Year
-1.69%
-1.69%

More News

Read More
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Via The Motley Fool
2 High-Yielding Dividend Investments to Buy for the Long Haul
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie
Via The Motley Fool
This Is the Best Dividend ETF You Can Buy
Via The Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
2 Reasons to Buy AbbVie, and 1 Reason to Sell
Via The Motley Fool
Better Growth Stock: AbbVie vs. Pfizer
Via The Motley Fool
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Via Benzinga
2 Relatively Safe Dividend Stocks You Won't Regret Owning
Via The Motley Fool
Is Big Pharma Coming For Your Cannabis Business?
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Price Over Earnings Overview: AbbVie
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
This Delivery Giant Is A 'Comeback Story' Plus Nike, AbbVie And Oracle: CNBC's 'Final Trades'
Via Benzinga
3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence
Via The Motley Fool
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
Via The Motley Fool
Use These 3 Strategies to Make $1,000 in Passive Income Per Year
Via The Motley Fool
AbbVie Provides Regulatory Update On Parkinson's Disease Drug Candidate
Via Benzinga
These 3 Dividend Growers Yield More Than the 10-Year Note
Via MarketBeat
Topics Bonds
Exposures Debt Markets
4 Top Value Stock ETFs for Long-Term Wealth Building
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.